ethyl 5-(2-naphthyl)-3-oxopentanoate | 452912-88-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: ethyl 5-(2-naphthyl)-3-oxopentanoate
• 英文别名: ethyl 5-naphthalen-2-yl-3-oxopentanoate
• CAS: 452912-88-8
• 化学式: C₁₇H₁₈O₃
• 分子量: 270.328
• InChiKey: URQGPHUVESDTDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 5-(2-naphthyl)-3-oxopentanoate 在 copper(l) iodide 、 Pd(AsPh₂)2 、 双(三甲基硅烷基)氨基钾 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 为溶剂， 生成 ethyl (E)-3-methyl-5-(2-naphthyl)-2-pentenoate
  参考文献：
  名称：

  Aromatic farnesyl diphosphate analogues

  摘要：

  A stereocontrolled vinyl triflate-based synthetic route has been used to prepare four analogues of farnesyl diphosphate (FPP) where the terminal isoprene units have been replaced with aromatic moieties. Two of these analogues exhibit no productive interaction with protein farnesyltransferase, but the 2-naphthyl derivative 2 is a modest inhibitor of the enzyme, and the para-biphenyl derivative 4 is a surprisingly effective alternative substrate. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00187-7
• 作为产物：
  描述：

  2-溴甲基萘 在 正丁基锂 、 二异丙胺 作用下， 以 四氢呋喃 为溶剂， 反应 4.17h， 以36%的产率得到ethyl 5-(2-naphthyl)-3-oxopentanoate
  参考文献：
  名称：

  [EN] SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF
  [FR] COMPOSES AMINO SUBSTITUES ET UTILISATION DE CES COMPOSE

  摘要：

  这项发明涉及具有结构式Ia或结构式Ib的新化合物：Ia Ib及其药用可接受的盐、互变异构体或体内可水解的前体，以及其组合物和使用方法。这些新化合物提供了治疗或预防与Aβ相关的病理学，如认知障碍、阿尔茨海默病、神经退行性疾病和痴呆症的方法。

  公开号：

  WO2006041404A1

文献信息

• Substituted Amino-Compounds and Uses Thereof
  申请人：Albert Jeffrey Scott

  公开号：US20090221579A1

  公开（公告）日：2009-09-03

  This invention relates to novel compounds having the structural formula Ia or formula Ib: Ia Ib and their pharmaceutically acceptable salts, tautomers or in vivo hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of Aβ related pathologies such as cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.

  本发明涉及具有结构式Ia或式Ib的新化合物：Ia Ib及其药学上可接受的盐、互变异构体或体内水解前体，以及其使用的组合物和方法。这些新化合物提供了治疗或预防与Aβ相关的病理学，如认知障碍、阿尔茨海默病、神经退行性和痴呆症的方法。
• Substituted Amino-Pyrimidones and Uses Thereof
  申请人：Albert Jeffrey Scott

  公开号：US20090062282A1

  公开（公告）日：2009-03-05

  This invention relates to novel compounds having the structural formula Ia or formula Ib below: (Ia, Ib), and their pharmaceutically acceptable salts, tautomers or in vivo hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of Aβ related pathologies such as cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.

  本发明涉及具有下列结构式Ia或结构式Ib的新化合物：（Ia，Ib），以及它们的药学上可接受的盐，互变异构体或体内水解前体，以及它们的组合物和使用方法。这些新化合物可用于治疗或预防与Aβ相关的病理学，如认知障碍，阿尔茨海默病，神经退行性和痴呆症。
• Application of Fragment-Based Lead Generation to the Discovery of Novel, Cyclic Amidine β-Secretase Inhibitors with Nanomolar Potency, Cellular Activity, and High Ligand Efficiency
  作者：Philip D. Edwards、Jeffrey S. Albert、Mark Sylvester、David Aharony、Donald Andisik、Owen Callaghan、James B. Campbell、Robin A. Carr、Gianni Chessari、Miles Congreve、Martyn Frederickson、Rutger H. A. Folmer、Stefan Geschwindner、Gerard Koether、Karin Kolmodin、Jennifer Krumrine、Russell C. Mauger、Christopher W. Murray、Lise-Lotte Olsson、Sahil Patel、Nate Spear、Gaochao Tian

  DOI：10.1021/jm070829p

  日期：2007.11.1

  Fragment-based lead generation has led to the discovery of a novel series of cyclic amidine-based inhibitors of beta-secretase (BACE-1). Initial fragment hits with an isocytosine core having millimolar potency were identified via NMR affinity screening. Structure-guided evolution of these fragments using X-ray crystallography together with potency determination using surface plasmon resonance and functional enzyme inhibition assays afforded micromolar inhibitors. Similarity searching around the isocytosine core led to the identification of a related series of inhibitors, the dihydroisocytosines. By leveraging the knowledge of the ligand-BACE-1 recognition features generated from the isocytosines, the dihydroisocytosines were efficiently optimized to submicromolar potency. Compound 29, with an IC50 of 80 nM, a ligand efficiency of 0.37, and cellular activity of 470 nM, emerged as the lead structure for future optimization.
• Oxaziridine-Mediated Intramolecular Amination of sp³-Hybridized C−H Bonds
  作者：Charles P. Allen、Tamas Benkovics、Amanda K. Turek、Tehshik P. Yoon

  DOI：10.1021/ja906183g

  日期：2009.9.9

  We describe a new oxaziridine-mediated approach to the amination of sp(3)-hybridized C-H bonds. In the presence of a copper(II) catalyst, N-sulfonyl oxaziridines participate in efficient intramolecular cyclization reactions to afford a variety of piperidine and tetrahydroisoquinoline structures. The aminal intermediates provide a convenient functional handle for further elaboration of these structures, demonstrating the utility of this new methodology for the rapid construction of structurally complex nitrogen-containing heterocycles.
• SUBSTITUTED AMINO-COMPOUNDS AND USES THEREOF
  申请人：AstraZeneca AB

  公开号：EP1802587A1

  公开（公告）日：2007-07-04